Amgen thyroid drug succeeds in late-stage trial

Aug 18 (Reuters) - Drugmaker Amgen Inc said its experimental drug to reduce thyroid levels in patients with chronic kidney disease met the main goal in a late-stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.